FDA Grants RMAT Designation to Mesoblast’s Revascor® for Severe Heart Disease in Children Mesoblast Limited, a global leader in allogeneic cellular medicines, has announced that its therapy, Revascor® (rexlemestrocel-L), has received the Regenerative Medicine Advanced Therapy (RMAT) design...

www.linkedin.com/pulse/fda-gr...

FDA Grants RMAT Designation to Mesoblast’s Revascor® for Severe Heart Disease in Children

kstrategyand.com/pharma-news

#Revascor #rexlemestrocelL #FDAApproval #RMATDesignation #ClinicalTrials #StemCellTherapy #Humanteconomy #Humantech #KStrategyand